• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Genentech wins FDA nod for subcutaneous formulation of arthritis drug

September 14, 2018 By Sarah Faulkner

Genentech logo updatedRoche‘s (OTC:RHHBY) Genentech reported this week that the FDA approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients two years and older.

The U.S. agency approved the intravenous formulation of Actemra for the same indication in 2011.

Systemic juvenile idiopathic arthritis affects roughly 30,000 children in the U.S., according to Roche. The condition brings about inflammation in one or more joints and a daily fever for at least two weeks. The company noted that the symptoms of SJIA can also include anemia, enlargement of the spleen or liver and inflammation of the lining of the heart and lungs.

“Systemic juvenile idiopathic arthritis is a rare, debilitating disease with limited treatment options,” Dr. Sandra Horning, chief medical officer & head of global product development, said in prepared remarks. “We are pleased to now offer physicians the flexibility to prescribe for children two years of age and older either Actemra IV, administered in a medical office, or Actemra subcutaneous, a prefilled syringe that can be injected at home.”

Roche’s approval for the subcutaneous formulation of Actemra was based on data from a 52-week Phase Ib pharmacokinetic/pharmacodynamic bridging study that evaluated the drug’s appropriate dosing regimen in children with SJIA. The 51-patient study included people with SJIA who were not responding to NSAIDs and corticosteroids.

The safety profile for the subcutaneous formulation of Actemra was consistent with the known safety profile of Actemra IV, Roche said, except for injection site reactions.

The efficacy of the subcutaneous formulation was determined based on PK exposure and extrapolation of the established efficacy of the IV formulation in SJIA patients, as well as the subcutaneous formulation of Actemra in patients with rheumatoid arthritis, Roche reported.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Food & Drug Administration (FDA), Orthopedics, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Genentech

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS